Business Context and Reporting Period
Oaktree Acquisition Corp. III Life Sciences, a Cayman Islands emerging growth company, filed this Form 8-K on October 25, 2024, to report the consummation of its initial public offering (IPO). The company is a special purpose acquisition company (SPAC) focused on the life sciences sector.
Key Financial Metrics
- Offering Proceeds: $175,000,000 in aggregate net proceeds from the IPO and Private Placement were placed in a trust account.
- Public Units Sold: 17,500,000 units at $10.00 per unit.
- Private Placement Units Sold: 550,000 units at $10.00 per unit to the Sponsor.
- Warrant Exercise Price: $11.50 per share for both Public and Private Placement warrants.
- Liquidity: Proceeds are held in a trust account with Continental Stock Transfer & Trust Company. Withdrawals are restricted to working capital (limited to $250,000 annually plus rollovers) and tax payments until a business combination is completed.
- Debt and Margins: The filing text does not provide specific values for debt, revenue, profit, or operating margins as the company has not yet commenced operations or completed a business combination.
Material Changes
The primary material change is the transition from a pre-IPO entity to a publicly traded company with $175,000,000 in trust assets. The company expects to file an amended audited balance sheet reflecting additional proceeds from the partial exercise of the underwriters' over-allotment option (1,699,029 Public Units) and additional Private Placement Units (33,981 units) closing on October 30, 2024.
Outlook, Risks, and Contingencies
- Business Combination Deadline: The company must complete its initial business combination within 24 months from the closing of the IPO (October 25, 2024).
- Redemption Rights: Public shareholders have the right to redeem their shares if the company fails to complete a business combination within the 24-month period or in connection with specific amendments to the charter.
- Trust Account Restrictions: Funds in the trust account generally cannot be released to the company until a business combination is completed, except for limited working capital and tax withdrawals.
- Over-Allotment: The final capitalization depends on the full exercise of the over-allotment option, which was partially exercised as of the filing date.
Investor Verification Checklist
- Verify the final amount of proceeds in the trust account after the October 30, 2024, closing of the over-allotment option.
- Review the audited balance sheet (Exhibit 99.1) included in the filing for the initial capitalization structure.
- Monitor the 24-month timeline for the initial business combination to assess redemption risks.
- Confirm the specific terms regarding the 1% U.S. federal excise tax exclusion mentioned in the trust withdrawal provisions.